[ad_1]
Sobi, an international biopharmaceutical company that is transforming the lives of people with rare diseases, today announced the release of data demonstrating the persistent burden of severe lower respiratory infection due to Respiratory Syncytial Virus (RSV). in premature newborns in the United States.
The data represent the results of the SENTINEL1 study, in which 46 American hospitals collected observational data on preterm infants born between 29 and 35 weeks of gestation who had not received RSV immunoprophylaxis and were subsequently hospitalized for RSV during the 2014-2015 period. 2015-2016 seasons of the VRS (from October to April approximately). A total of 1,378 infants hospitalized due to RSV infection were evaluated; Of these, 45% were admitted to the intensive care unit, 19% needed invasive mechanical ventilation, and two infants died. In the subgroup of younger and younger premature babies (born between 29 and 32 weeks of gestation and younger than 3 months when they were hospitalized for RSV), the burden was more severe: 69% of these infants were admitted to the USI and 41% needed an IMV. ; both deaths occurred in this group of younger and younger premature infants.
The study also revealed that among premature newborns released from hospital after birth during the RSV season (from November 1 to March 31, for this badysis) and readmitted later due to And RSV infection, 46% were readmitted within 30 days and 82% within 60 days. For the subgroup of premature newborns and preterm infants, the average hospitalization costs incurred during the two seasons were $ 122,301.
Results were similar between the 2014-15 and 2015-16 seasons, indicating the continuing burden of severe RSV disease on US-born preterm infants and the health care system. SENTINEL1 is the largest study ever conducted in the United States on premature newborns hospitalized with serious RSV infection confirmed in the laboratory. The data was published in the American Journal of Perinatology in April 2019 and is available online via open access.
RSV is the most common cause of hospitalization of infants in the United States. Despite the remarkable progress made over the past two decades in the management of premature infants, this study demonstrates that RSV causes significant morbidity in premature infants who do not receive RSV immunoprophylaxis. Evan J. Anderson, M.D., lead author of the paper and Associate Professor of Pediatrics and Medicine at Emory University School of Medicine, believes that this morbidity represents a considerable burden on the health system.
About Respiratory Syncytial Virus (RSV) Respiratory syncytial virus (RSV) is the most common cause of lower respiratory infection in infants and young children worldwide and is the most common cause of hospitalization of infants in the United States . Premature newborns are at a higher risk of hospitalization with RSV infection than full-term infants. There is currently no specific treatment for RSV once it is contracted, apart from supportive care while the disease is in progress, making the availability of RSV prophylaxis an essential priority of the RSV. public health.1
About Sobi in North America As a North American subsidiary of the international biopharmaceutical company Sobi "¢, our team supports Sobis' vision of providing sustainable access to innovative therapies and transforming the lives of people affected by rare diseases. We bring something rare to rare diseases "a belief in the strength of concentration, the power of agility and the potential of the people we pledge to serve. Our product portfolio includes several approved treatments, focused on immunology and genetics / metabolism. With its North American headquarters in the Boston area, its Canadian headquarters in the Toronto area and representatives from field sales, medical services and market access in North America, our team growing has a proven track record of commercial excellence. More information is available at www.sobi-northamerica.com. For more information on Sobi, visit www.sobi.com.
References:
1. Adamko DJ, Friesen M. Why does the respiratory syncytial virus seem to cause asthma? Journal of Allergy and Clinical Immunology. 2012; 130 (1): 101-102. doi: 10.1016 / j.jaci.2012.05.024.
Trista Morrison
781-810-0490
[email protected]
Source link
